Machine learning is driving efforts to classify MS into distinct subtypes that may predict disease course, but two experts debate whether this will advance patient care.
Skincare product maker Galderma, and pharmaceutical company Sandoz both returned to their home market this week, bringing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback